BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease
2011

BCG Vaccine and Neuroprotection in Parkinson's Disease Mice

Sample size: 6 publication 10 minutes Evidence: moderate

Author Information

Author(s): Yong Jing, Lacan Goran, Dang Hoa, Hsieh Terry, Middleton Blake, Wasserfall Clive, Tian Jide, Melega William P., Kaufman Daniel L.

Primary Institution: Department of Molecular and Medical Pharmacology, University of California Los Angeles

Hypothesis

Can BCG vaccination provide neuroprotective effects in a mouse model of Parkinson's disease?

Conclusion

BCG vaccination partially preserved dopamine system integrity and limited microglial activation in a mouse model of Parkinson's disease.

Supporting Evidence

  • BCG vaccination increased striatal dopamine levels by 16% compared to controls.
  • BCG vaccination prevented the increase in activated microglia in the substantia nigra after MPTP treatment.
  • Striatal DAT binding was significantly higher in BCG-vaccinated mice compared to unvaccinated controls.

Takeaway

Vaccinating mice with the BCG vaccine helped protect their brains from damage caused by a toxin related to Parkinson's disease.

Methodology

Mice were vaccinated with BCG or saline before being treated with MPTP, and various assays were conducted to measure dopamine levels and microglial activation.

Potential Biases

Potential bias in the interpretation of results due to the animal model used.

Limitations

The study was conducted in mice, and results may not directly translate to humans.

Participant Demographics

Male C57BL/6J mice, 8–10 weeks old.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0016610

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication